Início Osteonecrose maxilar induzida por agentes antirreabsortivos: conceitos, epidemiologia e conhecimento de profissionais...
medicamentos antirreabsortivos
Osteonecrose maxilar induzida por agentes antirreabsortivos: conceitos, epidemiologia e conhecimento de profissionais e usuários
Resumo:
Introduction: Medications called antiresorptives can be used as adjuvants in the treatment of bone and/or bone cancer diseases, with bisphosphonates, RANK-L inhibitors and antiangiogenic agents as the main representatives of the class. Review: The three drug classes have in common the possibility of causing, from their use, a rare adverse effect, but with extreme morbidity called Drug-Induced Maxillary Osteonecrosis (ONMIM). Due to the increasingly widespread use of these drugs for the treatment of different tumor and bone diseases, the knowledge of the medical, dental and also lay people, representing the patients themselves, about the possibility of the occurrence of ONMIM has become increasingly important. Many patients using antiresorptive medications do not have the knowledge or were not instructed by their physicians about the risk of their adverse effects; which can lead to inadvertent dental treatment and the onset of the disease. Discussion: Prevention before the use of medications through a careful assessment of the oral health condition and an elaborate plan of care between the oncology team and dentists, can reduce the risk of developing ONMIM. Final considerations: Health professionals must take responsibility for sharing their knowledge with patients and emphasize the importance of prevention through dental follow-up. And so, knowledge and awareness can minimize the incidence of the disease through preventive care.
Keywords: bone density conservation agents, denosumab, osteonecrosis, bisphosphonate-associated osteonecrosis of the jaw, antirresorptive medication, bisphosphonates.
Expandir Resumo
Acessar Texto Completo